These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36672611)

  • 21. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.
    Lorenz B; Künzel SH; Preising MN; Scholz JP; Chang P; Holz FG; Herrmann P
    Ophthalmology; 2024 Feb; 131(2):161-178. PubMed ID: 37704110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence.
    Gao J; Hussain RM; Weng CY
    Clin Ophthalmol; 2020; 14():3855-3869. PubMed ID: 33223822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
    Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
    Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Visual Acuity, Retinal Morphology, and Patients' Perceptions after Voretigene Neparovec-rzyl Therapy for RPE65-Associated Retinal Disease.
    Sengillo JD; Gregori NZ; Sisk RA; Weng CY; Berrocal AM; Davis JL; Mendoza-Santiesteban CE; Zheng DD; Feuer WJ; Lam BL
    Ophthalmol Retina; 2022 Apr; 6(4):273-283. PubMed ID: 34896323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic
    Kiraly P; Cottriall CL; Taylor LJ; Jolly JK; Cehajic-Kapetanovic J; Yusuf IH; Martinez-Fernandez de la Camara C; Shanks M; Downes SM; MacLaren RE; Fischer MD
    Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy.
    Kessel L; Christensen UC; Klemp K
    Ophthalmology; 2022 Nov; 129(11):1287-1293. PubMed ID: 35760216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa.
    Kwak JJ; Kim HR; Byeon SH
    Yonsei Med J; 2022 Jul; 63(7):701-705. PubMed ID: 35748082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.
    Maguire AM; Russell S; Chung DC; Yu ZF; Tillman A; Drack AV; Simonelli F; Leroy BP; Reape KZ; High KA; Bennett J
    Ophthalmology; 2021 Oct; 128(10):1460-1468. PubMed ID: 33798654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Classification and Growth Rate of Chorioretinal Atrophy after Voretigene Neparvovec-Rzyl for RPE65-Mediated Retinal Degeneration.
    Bommakanti N; Young BK; Sisk RA; Berrocal AM; Duncan JL; Bakall B; Mathias MT; Ahmed I; Chorfi S; Comander J; Nagiel A; Besirli CG
    Ophthalmol Retina; 2024 Jan; 8(1):42-48. PubMed ID: 37660736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research Network.
    Lorenz B; Tavares J; van den Born LI; Marques JP; Scholl HPN;
    Ophthalmic Res; 2021; 64(5):740-753. PubMed ID: 33684911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Objective Outcomes to Evaluate Voretigene Neparvovec Treatment Effects in Clinical Practice.
    Melillo P; Testa F; Di Iorio V; Karali M; Citro A; Della Corte M; Rossi S; Banfi S; Simonelli F
    Ophthalmol Retina; 2024 Jul; 8(7):688-698. PubMed ID: 38295874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial.
    Koenekoop RK; Sui R; Sallum J; van den Born LI; Ajlan R; Khan A; den Hollander AI; Cremers FP; Mendola JD; Bittner AK; Dagnelie G; Schuchard RA; Saperstein DA
    Lancet; 2014 Oct; 384(9953):1513-20. PubMed ID: 25030840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The phenotype of Severe Early Childhood Onset Retinal Dystrophy (SECORD) from mutation of RPE65 and differentiation from Leber congenital amaurosis.
    Weleber RG; Michaelides M; Trzupek KM; Stover NB; Stone EM
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):292-302. PubMed ID: 20811047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy.
    Jalil A; Ivanova T; Moussa G; Parry NRA; Black GCM
    Eye (Lond); 2023 Jun; 37(9):1874-1877. PubMed ID: 36163489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Voretigene neparvovec-rzyl for treatment of
    Ciulla TA; Hussain RM; Berrocal AM; Nagiel A
    Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547
    [No Abstract]   [Full Text] [Related]  

  • 36. Gene therapy for RPE65-related retinal disease.
    Miraldi Utz V; Coussa RG; Antaki F; Traboulsi EI
    Ophthalmic Genet; 2018 Dec; 39(6):671-677. PubMed ID: 30335549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec.
    Stingl K; Kempf M; Bartz-Schmidt KU; Dimopoulos S; Reichel F; Jung R; Kelbsch C; Kohl S; Kortüm FC; Nasser F; Peters T; Wilhelm B; Wissinger B; Wozar F; Zrenner E; Fischer MD; Stingl K
    Br J Ophthalmol; 2022 Jun; 106(6):831-838. PubMed ID: 33472769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Full-field Scotopic Threshold Improvement after Voretigene Neparvovec-rzyl Treatment Correlates with Chorioretinal Atrophy.
    Stingl K; Stingl K; Schwartz H; Reid MW; Kempf M; Dimopoulos S; Kortuem F; Borchert MS; Lee TC; Nagiel A
    Ophthalmology; 2023 Jul; 130(7):764-770. PubMed ID: 36822437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.
    Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.
    Hauswirth WW; Aleman TS; Kaushal S; Cideciyan AV; Schwartz SB; Wang L; Conlon TJ; Boye SL; Flotte TR; Byrne BJ; Jacobson SG
    Hum Gene Ther; 2008 Oct; 19(10):979-90. PubMed ID: 18774912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.